FDA expands J&J’s Rybrevant Faspro label with head and neck cancer approval
The accelerated approval marks the first indication beyond lung cancer for J&J’s bispecific antibody.
Accelerate decision-making with data-led confidence
Combine proprietary data, human expertise, and purpose-built AI to uncover insights and accelerate better business decisions.
Discover our solutions
Drug delivery’s next bottleneck isn’t innovation, it’s industrial capacity
Australia starts investigation into OpenAI Medicare breach
How DFE Pharma supports confident continuous manufacturing decisions
Industry partnership will determine the success of the transition to low-GWP pMDIs